98%
921
2 minutes
20
Importance: A lack of transparent reporting of race and ethnicity in clinical research limits the ability to identify health inequities and evaluate to what extent clinical research includes diverse populations.
Objective: To identify study characteristics associated with reporting race and ethnicity of clinical study participants and to document temporal trends in race and ethnicity reporting on clinicaltrials.gov.
Design: Cross-sectional analysis of interventional trials and observational studies from 2009-2024; multivariable logistic regression assessed study-level factors associated with reporting race and ethnicity.
Setting: Global registry of clinical studies (clinicaltrials.gov).
Participants: 58,163 studies with posted results and without early termination.
Exposures: Study characteristics: sponsor trial phase, study type, and country.
Main Outcomes And Measures: Reporting of race, reporting of ethnicity, reporting of both.
Results: Among 58,163 studies (mean enrollment=1,215 participants), 44.8% did not report race or ethnicity to the repository (mean enrollment=1,481 participants). The proportion of studies reporting both race and ethnicity rose from 7.4% in 2013 to 54.6% in 2024. In multivariable models, observational studies had lower odds of reporting race and ethnicity (odds ratio[OR]=0.55, 95% confidence interval[CI]=0.49-0.61) compared with interventional trials. Phase 4 trials were least likely phase to report race and ethnicity (OR=0.32; CI=0.29-0.35), and studies with only National Institute of Health funding were more likely to report race and ethnicity compared to studies with any industry funding or sponsorship (OR=1.70, CI=1.61-1.79). For studies that reported race, White participants comprised ≥50% each year based on study-level percentages; proportions of Asian participants declined, and Black participants fluctuated. 'Not Hispanic or Latino' remained ≥80% of reported ethnicity annually.
Conclusions And Relevance: Race and ethnicity reporting on clinicaltrials.gov has improved markedly yet remains incomplete, with shortfalls in late-phase and observational studies.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12330421 | PMC |
http://dx.doi.org/10.1101/2025.07.21.25331865 | DOI Listing |
J Am Acad Orthop Surg Glob Res Rev
September 2025
From the University of California, Riverside, Riverside, CA (Arroyo, Moore); the Birmingham Heersink School of Medicine, University of Alabama, Birmingham, AL (Cruz); the Warren Alpert Medical School, Brown University, Providence, RI (Rodarte); Department of Orthopaedic Surgery, Banner University Sp
Introduction: Orthopaedic surgery has historically been among the least ethnically diverse fields in medicine. The latest American Academy of Orthopaedic Surgeons (AAOS) Census report in 2018 indicates that only 2.2% of all practicing orthopaedic surgeons in the United States identify as Hispanic/Latino.
View Article and Find Full Text PDFJ Surg Oncol
September 2025
School of Medicine, Creighton University; Omaha, Nebraska, USA.
Introduction: Time to initiation of therapy in oncological care is an influential factor in disease progression and survival outcomes in many cancer types. We aim to identify factors associated with delayed time to treatment (TTT) in high-grade osteosarcoma and its relationship to disease-specific survival (DSS).
Methods: The SEER database was queried for biopsy-confirmed cases of high-grade osteosarcoma between 2000 and 2021 using ICD-O-3 histology codes 9180/3-9194/3 and primary site codes C40.
Anesthesiology
October 2025
Mayo Clinic, Phoenix, Arizona.
Anesthesiology
October 2025
Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts.
Anesthesiology
October 2025
University of Health Sciences, Konya City Hospital, Konya, Turkey.